Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
// Helena Cirenajwis 1 , Henrik Ekedahl 2 , Martin Lauss 1 , Katja Harbst 1 , Ana Carneiro 1,3 , Jens Enoksson 4 , Frida Rosengren 1 , Linda Werner-Hartman 1 , Therese Törngren 1 , Anders Kvist 1 , Erik Fredlund 5 , Pär-Ola Bendahl 1 , Karin Jirström 4 , Lotta Lundgren 1,3 , Jillian Howlin 1 , Åke Borg 1 , Sofia K. Gruvberger-Saal 1 , Lao H. Saal 1 , Kari Nielsen 6 , Markus Ringnér 1 , Hensin Tsao 7,8 , Håkan Olsson 1,3 , Christian Ingvar 2 , Johan Staaf 1 , Göran Jönsson 1 1 Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, Lund, Sweden 2 Department of Clinical Sciences, Division of Surgery, Lund University, Lund, Sweden 3 Department of Oncology, Skåne University Hospital, Lund University, Lund, Sweden 4 Department of Clinical Pathology, Skåne University Hospital, Lund University, Lund, Sweden 5 Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden 6 Department of Dermatology, Helsingborg General Hospital, Helsingborg, Sweden 7 Department of Dermatology, Harvard Medical School, Boston, USA 8 Wellman Center for Photomedicine, MGH Cancer Center, Massachusetts General Hospital, Boston, USA Correspondence to: Göran Jönsson, email: // Keywords : gene expression, melanoma, BRAF, BRAF inhibitor, mutation Received : January 09, 2015 Accepted : February 27, 2015 Published : March 26, 2015 Abstract Melanoma is currently divided on a genetic level according to mutational status. However, this classification does not optimally predict prognosis. In prior studies, we have defined gene expression phenotypes (high-immune, pigmentation, proliferative and normal-like), which are predictive of survival outcome as well as informative of biology. Herein, we employed a population-based metastatic melanoma cohort and external cohorts to determine the prognostic and predictive significance of the gene expression phenotypes. We performed expression profiling on 214 cutaneous melanoma tumors and found an increased risk of developing distant metastases in the pigmentation (HR, 1.9; 95% CI, 1.05-3.28; P =0.03) and proliferative (HR, 2.8; 95% CI, 1.43-5.57; P =0.003) groups as compared to the high-immune response group. Further genetic characterization of melanomas using targeted deep-sequencing revealed similar mutational patterns across these phenotypes. We also used publicly available expression profiling data from melanoma patients treated with targeted or vaccine therapy in order to determine if our signatures predicted therapeutic response. In patients receiving targeted therapy, melanomas resistant to targeted therapy were enriched in the MITF-low proliferative subtype as compared to pre-treatment biopsies ( P =0.02). In summary, the melanoma gene expression phenotypes are highly predictive of survival outcome and can further help to discriminate patients responding to targeted therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
A landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610 · cited 1×
“Previously, large screening efforts have uncovered novel melanoma driver genes using whole-exome sequencing [20, 21].”
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548 · cited 1×
“MITF is a melanocyte differentiation transcription factor considered to be the master regulator in pigmentation, but has also been described as a lineagespecific oncogene in melanoma [28, 29].”
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
Krauthammer, M., Kong, Y., Ha, B. H., Evans, P., Bacchiocchi, A., McCusker, J. P., Cheng, E., Davis, M. J., Goh, G., Choi, M., et al. (2012) · Nature Genetics · doi:10.1038/ng.2359 · Cited by 1,191 · cited 1×
“Previously, large screening efforts have uncovered novel melanoma driver genes using whole-exome sequencing [20, 21].”
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
Müller, J., Krijgsman, O., Tsoi, J., Robert, L., Hugo, W., Song, C., Kong, X., Possik, P. A., Cornelissen-Steijger, P. D. M., Foppen, M. H. G., et al. (2014) · Nature Communications · doi:10.1038/ncomms6712 · Cited by 639 · cited 1×
“These results are in line with two recent studies showing that the MITF-low state is associated with an intrinsic resistance to MAPK pathway inhibition, as well as with an acquired resistance observed later in initially responding melanomas [26, 27].”
Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy
Ulloa-Montoya, F., Louahed, J., Dizier, B., Gruselle, O., Spiessens, B., Lehmann, F. F., Suciu, S., Kruit, W. H. J., Eggermont, A. M. M., Vansteenkiste, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.3762 · Cited by 436 · cited 7×
“vaccines or immune checkpoint blockades, with the latter approach utilizing monoclonal antibodies directed against the inhibitory immune receptors CTLA-4, PD-1 or PD-L1 [12-14].”
InfluentialAdjustment of systematic microarray data biases
Benito, M., Parker, J., Du, Q., Wu, J., Xiang, D., Perou, C. M., & Marron, J. S. (2004) · Bioinformatics · doi:10.1093/bioinformatics/btg385 · Cited by 426
Long, G. V., Fung, C., Menzies, A. M., Pupo, G. M., Carlino, M. S., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J. F., Saw, R. P., et al. (2014) · Nature Communications · doi:10.1038/ncomms6694 · Cited by 375 · cited 8×
“The gene expression phenotypes and their clinical relevance were Oncotarget12307www.impactjournals.com/oncotarget evaluated in three independent external datasets obtained from GEO (GSE50509 [16]; GSE61992 [17]; GSE35640 [14]).”
InfluentialMonitoring of Technical Variation in Quantitative High-Throughput Datasets
Lauss, M., Visne, I., Kriegner, A., Ringnér, M., Jönsson, G., & Höglund, M. (2013) · Cancer Informatics · doi:10.4137/cin.s12862 · Cited by 74 · cited 1×
“The data were analyzed for technical variations using principal component analysis (PCA), (Figure S4) [32].”
Self-citation
Cited by
The immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263
Conserved pan-cancer microenvironment subtypes predict response to immunotherapy
Bagaev, A., Kotlov, N., Nomie, K., Svekolkin, V., Gafurov, A., Isaeva, O., Osokin, N., Kozlov, I., Frenkel, F., Gancharova, O., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.04.014 · Cited by 1,302
Lauss, M., Donia, M., Harbst, K., Andersen, R., Mitra, S., Rosengren, F., Salim, M., Vallon-Christersson, J., Törngren, T., Kvist, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01460-0 · Cited by 470
Self-citationWei, C., Sun, W., Shen, K., Zhong, J., Liu, W., Gao, Z., Xu, Y., Wang, L., Hu, T., Ren, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43980-y · Cited by 49
Metadata
- Authors
- Cirenajwis, H., Ekedahl, H., Lauss, M., Harbst, K., Carneiro, A., Enoksson, J., Rosengren, F., Werner-Hartman, L., Törngren, T., Kvist, A., Fredlund, E., Bendahl, P.-O., Jirström, K., Lundgren, L., Howlin, J., Borg, Å., Gruvberger-Saal, S. K., Saal, L. H., Nielsen, K., Ringnér, M., Tsao, H., Olsson, H., Ingvar, C., Staaf, J., & Jönsson, G.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-03-26
- Volume
- 6
- Issue
- 14
- Pages
- 12297-12309
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1854900052
- Cited by
- 192
- References
- 12
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.